<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Scibase Holding Ab — News on 6ix</title>
<link>https://6ix.com/company/scibase-holding-ab</link>
<description>Latest news and press releases for Scibase Holding Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 14:17:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/scibase-holding-ab" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57079beedb30cb6f851bf.webp</url>
<title>Scibase Holding Ab</title>
<link>https://6ix.com/company/scibase-holding-ab</link>
</image>
<item>
<title>SciBase publishes the Annual report for 2025</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-publishes-the-annual-report-for-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-publishes-the-annual-report-for-2025-1</guid>
<pubDate>Mon, 27 Apr 2026 14:17:00 GMT</pubDate>
<description>SciBase hereby announces that the Annual report for 2025 is available at the Company's website www.scibase.com.</description>
</item>
<item>
<title>Notice to attend the annual general meeting in Scibase Holding AB (publ)</title>
<link>https://6ix.com/company/scibase-holding-ab/news/notice-to-attend-the-annual-general-meeting-in-scibase-holding-ab-publ-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/notice-to-attend-the-annual-general-meeting-in-scibase-holding-ab-publ-1</guid>
<pubDate>Tue, 14 Apr 2026 11:08:00 GMT</pubDate>
<description>Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 19 May 2026 at 10:00 CEST at BAHR Advokatbyrå, Birger Jarlsgatan 16, in Stockholm. The registration to the meeting will open at 09:30 CEST.</description>
</item>
<item>
<title>SciBase reaches milestone with over 400,000 tests sold with Nevisense</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-reaches-milestone-with-over-400000-tests-sold-with-nevisense-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-reaches-milestone-with-over-400000-tests-sold-with-nevisense-1</guid>
<pubDate>Tue, 07 Apr 2026 07:02:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced a significant milestone with over 400,000 Nevisense tests sold worldwide.</description>
</item>
<item>
<title>New Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment</title>
<link>https://6ix.com/company/scibase-holding-ab/news/new-study-positions-nevisenses-eis-as-a-valuable-and-sensitive-tool-for-assessing-skin-barrier-impairment-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/new-study-positions-nevisenses-eis-as-a-valuable-and-sensitive-tool-for-assessing-skin-barrier-impairment-1</guid>
<pubDate>Tue, 10 Mar 2026 12:27:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, is pleased to announce the publication of a pivotal study in the leading journal Contact Dermatitis. The study, titled "Assessing Skin Barrier Integrity: A Comparative Study Using Transepidermal Water Loss, Electrical Impedance Spectroscopy and Corneometry," confirms that Nevisense Electrical Impedance Spectroscopy (EIS) is a robust and effective method for studying skin barrier i</description>
</item>
<item>
<title>New Publication: US clinicians' real-world Nevisense experience improves melanoma detection</title>
<link>https://6ix.com/company/scibase-holding-ab/news/new-publication-us-clinicians-real-world-nevisense-experience-improves-melanoma-detection-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/new-publication-us-clinicians-real-world-nevisense-experience-improves-melanoma-detection-1</guid>
<pubDate>Thu, 05 Mar 2026 07:24:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announced that Stephen D. Hess, MD, PhD, FAAD, has published a clinical article highlighting his real-world experience integrating Nevisense into routine melanoma detection. The article was published in The Dermatologist, a leading U.S. clinical dermatology journal.</description>
</item>
<item>
<title>SciBase receives approval by FDA for extended labelling in the US</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-receives-approval-by-fda-for-extended-labelling-in-the-us-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-receives-approval-by-fda-for-extended-labelling-in-the-us-1</guid>
<pubDate>Mon, 02 Mar 2026 07:21:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure. Previously, the labelling only specified dermatologists as users but now it also includes healthcare professionals such as physician assistants and medical assistants working at der</description>
</item>
<item>
<title>SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibases-nevisense-eis-included-in-the-us-nccn-guidelines-for-melanoma-which-supports-the-use-of-eis-in-the-detection-of-melanoma-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibases-nevisense-eis-included-in-the-us-nccn-guidelines-for-melanoma-which-supports-the-use-of-eis-in-the-detection-of-melanoma-1</guid>
<pubDate>Thu, 19 Feb 2026 13:14:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense (EIS) is included in the US National Comprehensive Cancer Network(NCCN) Clinical Practice Guidelines in Oncology formelanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma.</description>
</item>
<item>
<title>A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns</title>
<link>https://6ix.com/company/scibase-holding-ab/news/a-new-study-demonstrates-that-nevisense-can-predict-atopic-dermatitis-in-newborns-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/a-new-study-demonstrates-that-nevisense-can-predict-atopic-dermatitis-in-newborns-1</guid>
<pubDate>Tue, 17 Feb 2026 14:27:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announces that results from a new study will be presented in an oral presentation at the AAAAI conference in Philadelphia February 27 - March 2.</description>
</item>
<item>
<title>SciBase: Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-recalculation-of-warrants-of-series-to-2-following-rights-issue-and-updated-last-day-of-trading-in-bta-from-the-rights-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-recalculation-of-warrants-of-series-to-2-following-rights-issue-and-updated-last-day-of-trading-in-bta-from-the-rights-issue-1</guid>
<pubDate>Fri, 06 Feb 2026 07:17:00 GMT</pubDate>
<description>In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of shares that the board of directors resolved upon o</description>
</item>
<item>
<title>SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-announces-final-outcome-of-the-rights-issue-and-the-resolution-on-a-set-off-issue-within-the-framework-of-the-offer-to-repurchase-outstanding-warrants-of-series-to-2-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-announces-final-outcome-of-the-rights-issue-and-the-resolution-on-a-set-off-issue-within-the-framework-of-the-offer-to-repurchase-outstanding-warrants-of-series-to-2-1</guid>
<pubDate>Tue, 27 Jan 2026 18:29:00 GMT</pubDate>
<description>SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on 29 December 2025 (the "Rights Issue"). The Rights Issue has been subscribed to 96.4 percent, of which approximately 61.3 percent has been subscribed for with the support of subscription rights and approximately 35.1 percent without the support of subscription rights. Through the Rights Issue, the Company will receive approximately 79.9 MSEK before dedu</description>
</item>
<item>
<title>Change of date for publication of the year-end report for the financial year 2025</title>
<link>https://6ix.com/company/scibase-holding-ab/news/change-of-date-for-publication-of-the-year-end-report-for-the-financial-year-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/change-of-date-for-publication-of-the-year-end-report-for-the-financial-year-2025-1</guid>
<pubDate>Mon, 26 Jan 2026 18:19:00 GMT</pubDate>
<description>The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has resolved to postpone the publication of the year-end report for the financial year 2025 to March 13, 2026. The reason for the postponement is to align the trading restriction period with the ongoing rights issue, the subscription period of which ends today, January 26, 2026.</description>
</item>
<item>
<title>Increased commitment in SciBase rights issue</title>
<link>https://6ix.com/company/scibase-holding-ab/news/increased-commitment-in-scibase-rights-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/increased-commitment-in-scibase-rights-issue-1</guid>
<pubDate>Thu, 22 Jan 2026 14:35:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announces it has been informed that Life Science Investment Fund 1, one of SciBase larger shareholders have subscribed for their pro rata share of 5.0 percent in the ongoing rights issue. Furthermore, members of SciBase management and board have subscribed for shares in the rights issue totalling 0.6 MSEK in addition to their pro-rata commitments.</description>
</item>
<item>
<title>SciBase publishes information document regarding rights issue</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-publishes-information-document-regarding-rights-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-publishes-information-document-regarding-rights-issue-1</guid>
<pubDate>Fri, 09 Jan 2026 15:17:00 GMT</pubDate>
<description>The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue of shares of approximately SEK 83 million (the "Rights Issue") resolved by the Board of Directors of the Company on 29 December 2025. The information document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website and will also be available on Bergs Securities AB's ("Bergs Securities") website</description>
</item>
<item>
<title>SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-announces-outcome-of-the-offer-to-repurchase-outstanding-warrants-of-series-to-2-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-announces-outcome-of-the-offer-to-repurchase-outstanding-warrants-of-series-to-2-1</guid>
<pubDate>Fri, 09 Jan 2026 12:44:00 GMT</pubDate>
<description>SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the repurchase offer for all warrants of series TO 2 resolved by the Board of Directors on 7 November 2025 (the "TO 2 Offer"). The outcome shows that holders of a total of 418,150,952 warrants of series TO 2 have accepted the TO 2 Offer where two (2) warrants of series TO 2 entitle to one (1) newly issued share in the Company. The outcome of the TO 2 Offer corresponds to approximately 83.9 percent of all outsta</description>
</item>
<item>
<title>The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million</title>
<link>https://6ix.com/company/scibase-holding-ab/news/the-board-of-directors-of-scibase-resolves-on-a-previously-communicated-rights-issue-of-shares-of-approximately-sek-83-million-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/the-board-of-directors-of-scibase-resolves-on-a-previously-communicated-rights-issue-of-shares-of-approximately-sek-83-million-1</guid>
<pubDate>Mon, 29 Dec 2025 13:16:00 GMT</pubDate>
<description>The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, based on the authorization granted by the Annual General Meeting on 17 June 2025, resolved on a rights issue of shares of approximately SEK 83 million, before deduction of transaction costs, (the "Rights Issue"), in accordance with the intention published by the Company through a press release on 7 November 2025. All existing shareholders will receive one (1) subscription right for each share held on the</description>
</item>
<item>
<title>SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-expands-its-intellectual-property-portfolio-to-include-the-analysis-of-the-epithelial-skin-barrier-with-new-european-patent-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-expands-its-intellectual-property-portfolio-to-include-the-analysis-of-the-epithelial-skin-barrier-with-new-european-patent-1</guid>
<pubDate>Thu, 11 Dec 2025 14:28:00 GMT</pubDate>
<description>SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that it has been granted a new European patent, EP3876835B1 "Medical Devices for Analyzing Epithelial Barrier Function", further strengthening its already extensive intellectual property portfolio. This newly granted patent aligns with the company's strategic focus on developing medical and research solutions that advance the understanding of the epithelial skin barrier.</description>
</item>
<item>
<title>SciBase publishes information document regarding the offer to repurchase outstanding warrants of series TO 2</title>
<link>https://6ix.com/company/scibase-holding-ab/news/scibase-publishes-information-document-regarding-the-offer-to-repurchase-outstanding-warrants-of-series-to-2-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/scibase-publishes-information-document-regarding-the-offer-to-repurchase-outstanding-warrants-of-series-to-2-1</guid>
<pubDate>Fri, 05 Dec 2025 17:42:00 GMT</pubDate>
<description>SciBase Holding AB (publ) ("SciBase" or the "Company") publishes an information document in connection with the offer to repurchase all outstanding warrants of series TO 2 in SciBase (the "TO 2 Offer"), which was announced by SciBase on 7 November 2025. The information document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website and will also be available on Bergs Securities AB's ("Bergs Securities") website https://www.bergssecurities.s</description>
</item>
<item>
<title>Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)</title>
<link>https://6ix.com/company/scibase-holding-ab/news/bulletin-from-the-extraordinary-general-meeting-in-scibase-holding-ab-publ-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/bulletin-from-the-extraordinary-general-meeting-in-scibase-holding-ab-publ-1</guid>
<pubDate>Fri, 05 Dec 2025 09:38:00 GMT</pubDate>
<description>Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposal presented in the notice to convene the meeting (which is available on the Company's website (www.scibase.com).</description>
</item>
<item>
<title>Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors</title>
<link>https://6ix.com/company/scibase-holding-ab/news/former-novo-nordisk-executive-jesper-hoiland-joins-alva-therapeutics-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/former-novo-nordisk-executive-jesper-hoiland-joins-alva-therapeutics-board-of-directors-1</guid>
<pubDate>Wed, 03 Dec 2025 13:31:00 GMT</pubDate>
<description>Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity—announced that Mr. Jesper Høiland has been appointed to Alva Board of Directors.</description>
</item>
<item>
<title>The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a rights issue of shares of approximately SEK 83 million</title>
<link>https://6ix.com/company/scibase-holding-ab/news/the-board-of-directors-in-scibase-resolves-on-an-offer-to-repurchase-outstanding-warrants-of-series-to-2-and-intends-to-resolve-on-a-rights-issue-of-shares-of-approximately-sek-83-million-1</link>
<guid isPermaLink="true">https://6ix.com/company/scibase-holding-ab/news/the-board-of-directors-in-scibase-resolves-on-an-offer-to-repurchase-outstanding-warrants-of-series-to-2-and-intends-to-resolve-on-a-rights-issue-of-shares-of-approximately-sek-83-million-1</guid>
<pubDate>Fri, 07 Nov 2025 07:50:00 GMT</pubDate>
<description>The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved to make a repurchase offer for all 498,534,835 outstanding warrants of series TO 2 in the Company (the "TO 2 Offer").In the TO 2 Offer, two (2) warrants of series TO 2 will entitle the holder to one (1) new share in the Company. Through the TO 2 Offer, a total of 249,267,417 new shares may be issued. A group of investors who holds warrants of series TO 2 have, in total, entered into irrevocable un</description>
</item>
</channel>
</rss>